



Priority-driven Collaborative Cancer Research Scheme 2023

Cancer Australia, Australian Lions Childhood Cancer Research Foundation, Bowel Cancer Australia, Can Too Foundation, Cooper Rice-Brading Foundation, Leukaemia Foundation, Lung Foundation Australia, My Room Children's Cancer Charity Limited, National Breast Cancer Foundation, Neuroblastoma Australia, Ovarian Cancer Research Foundation, and The Kids' Cancer Project are pleased to announce successful applicants in the 2023 round of the Priority-driven Collaborative Cancer Research Scheme.

Boyle, Sarah

Centre for Cancer Biology (University of South Australia and SA Pathology)

Tackling breast cancer growth and metastasis by suppressing ROCK-regulated paracrine signalling.

Funded by: Cancer Australia, Can Too Foundation

Byrne, Hilary

University of Sydney

How are you breathing today?

Funded by: Cancer Australia, Lung Foundation Australia

Cole, Alexander

Centenary Institute

Treating chemoresistant ovarian cancer: Blocking follistatin signalling to enhance the effects of chemotherapy and prevent recurrence of chemoresistant disease.

Funded by: Cancer Australia, Ovarian Cancer Research Foundation

D'Andrea, Richard

University of South Australia

Integrating cancer germline genetics, precision medicine and oncology to optimise management of paediatric AML.

Funded by: Cancer Australia, My Room Children's Cancer Charity Limited, The Kids' Cancer Project

Dun, Matt

The University of Newcastle

Taming free radicals to silence the epigenome of kinase active paediatric cancers.

Funded by: Cancer Australia, The Kids' Cancer Project

Hindley, Nicholas

University of Sydney

From relativity to respiration: How ideas from Einstein's general theory enable adaptive radiation therapy for lung cancer patients.

Funded by: Cancer Australia, Lung Foundation Australia

McDonald, Michelle

University of Sydney

The Skeleton: A Reservoir for Metastatic Outgrowth.

Funded by: Cancer Australia



Park, Susanna

University of Sydney

Harnessing metabolic, genetic and protein biomarkers to predict neurotoxicity in taxane-treated cancer patients (NeuroTax): A prospective validation cohort study

Funded by: Cancer Australia

Samuel, Michael

University of South Australia

Insights from the functional tumour secretome: new opportunities to monitor and halt colorectal cancer progression.

Funded by: Bowel Cancer Australia

Sanij, Elaine

St Vincent's Institute of Medical Research

Harnessing the nucleolar stress response in cancer therapy.

Funded by: Cancer Australia

Schumacher, Oliver

Edith Cowan University

Exercise as a novel therapeutic approach for sensitising prostate cancer to radiotherapy.

Funded by: Cancer Australia, Can Too Foundation

Selth, Luke

Flinders University

A novel hormonal therapy to treat lethal prostate cancer.

Funded by: Cancer Australia

Sutherland, Kate

The Walter and Eliza Hall Institute of Medical Research

Exploiting cell-of-origin features to improve treatment for KEAP1-mutant lung cancer.

Funded by: Cancer Australia

Tavakoli Shirazi, Paniz

The Council of the Queensland Institute of Medical Research

Effect of co-occurring mutations on therapy response and resistance.

Funded by: Cancer Australia

Thurgood, Lauren

Flinders University

Non-canonical PI3K targeting - novel therapies to exploit the lipid dependency of CLL.

Funded by: Leukaemia Foundation

Vandyke, Kate

The University of Adelaide

Priming the blood-brain barrier to improve drug delivery and treatment outcomes in diffuse midline glioma.

Funded by: Cancer Australia, Australian Lions Childhood Cancer Research Foundation, The Kids' Cancer Project



Australian Government
Cancer Australia

Ziegler, David

University of New South Wales

Unlocking the potential of the blood-brain barrier in the fight against paediatric brain gliomas

Funded by: Cancer Australia